STIM: Neuronetics 2022-07-19 07:00:00 NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
I like the recent MACD cross and that the most recent candle tested two fib levels and closed over the .382 level. Also after an extreme sell off price seems to have bottomed at 4.61. The ADX shows a relatively strong trend with the directional indicators moving in a bullish direction. targeting: 5.63, 5.81, 6.04
MACD is crossing and the price has consolidated around $12.17 for several trading days. I will try to add between $12.17 and $11.60 with a stop at at $11.36 Target: $16.34
$STIM - looks like it might be good here for a long position. My stop is $16.50
I should have got in yesterday. I am considering an entry tomorrow on a pull back. It's opex so we may get one. I like swinging this stock.
$STIM - added to my biotech/genome category It has the same "chicken-beak" patterns as EDIT, CRSP, BNGO and others. I'm swinging this stock. It has buyer support at $14.00 level. We are barely above that, so feels ok to keep adding to this swing trade.
Lets see if this wanna play to target 8+ Just to follow the stock but i see a small retrancement befor it keep going forward
STIM looks like its ready for its next leg up as the MACD starts to cross, it broke thru the descending trendline today and today's candle closed above 6.34 (100% Fib level) assuming it can break thru resistance at 6.85 I think this goes much higher. First target 7.82 and on to 10.21 in the longer term
The STIM chart looks very bullish with a recent MACD cross and the 9ema crossing the 20ema. Also the .23 fib level was tested twice and should act as a support level. First target 5.82 then 6.26 in the short term.
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education,...
Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer Keith’s track record includes successfully growing multiple MedTech businesses, driving innovation and impressive market development We believe that Keith’s experience in commercializing products that involve both capital equipment and recurring revenue streams is...
Got in and out quickly. Maybe Ill pick up more, who knows but ill watch and see how I play my next move...
So, I picked up a quick 100 shares @ 2.65 and sold for 2. 85 as it drops a bit, I think i'll pick up more on the trending going up
#3(scanner) 10M float, very low volume.